BMB Section seminar: "Inside-out regulation of Fc receptors; consequences for antibody therapy of cancer"
Dr. Jeanette Leusen
University Medical Center Utrecht, Netherland
Dr. Jeanette Leusen, University Medical Center Utrecht, Netherland. (Photo: www.tumor-immunology-utrecht.nl)
Fc receptors (FcR) are expressed on immune cells and bind to the Fc tail portion of antibodies. This interaction is essential for FcR-mediated signaling and triggering of cellular effector functions. FcR activation is tightly regulated, to prevent activation without a ‘danger signal’ or by non-antigen-bound antibodies. FcR activation can be regulated by inside-out signaling, a process well-known for integrins but also described for FcγRI (CD64), FcγRIIa (CD32a), and FcαRI (CD89). The Danger signal can be provided by cytokines at the site of infection/inflammation that can efficiently activate these FcR. Key mechanisms in inside-out signaling are conformational changes, (de)phosphorylation, clustering, and cytoskeleton rearrangements. Research on FcR has gained momentum with the rise of monoclonal antibodies (mAb) entering the clinic for treatment of cancer and other diseases. FcR engagement can induce killing of opsonized tumor cells. Cytokine stimulation of FcR to increase the binding of FcR avidity to mAb might be an effective strategy to enhance the clinical outcome of mAb therapy. The mechanisms of FcγRI and FcαR activation will be discussed in more detail, and the consequences for (IgA) antibody therapy.
For more info visit UMC Utrecth
It is a great pleasure to invite you to a guest lecture by Dr. Jeanette Leusen from University Medical Center Utrecht, Netherland. Dr. Leusen is the head of the Immunotherapy group at the Laboratory for Translational Immunology, and her research is focused on the working mechanisms of therapeutic antibodies and Fc receptors in cancer, autoimmune disease, and infection. Dr. Leusen is visiting Oslo as an opponent for Stian Foss' PhD defense.
Refreshments will be served before the lecture. All welcome!